Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age less than or equal to 34 weeks~* Postnatal age less than or equal to 7 days (168 hours).~* Assisted ventilation for hypoxemic respiratory failure.~* Diagnosis of NHRF including perinatal aspiration syndrome (meconium, blood, or amniotic fluid), suspected/proven pneumonia/sepsis, respiratory distress syndrome, idiopathic persistent pulmonary hypertension of the newborn (PPHN) or suspected pulmonary hypoplasia.~* Receiving INO for at least 1 hour and not \>72 hours.~* Oxygenation Index (OI ) ≥ 15 on any 2 arterial blood gases 15 minutes to 12 hours apart while on INO.~* An indwelling arterial line is present~Exclusion Criteria:~* Any infant in whom a decision has been made not to provide full treatment (e.g. chromosomal anomalies, severe birth asphyxia).~* Known structural congenital heart disease except patent ductus arteriosus and atrial/ventricular level shunts.~* Congenital diaphragmatic hernia.~* Thrombocytopenia unresponsive to platelet transfusion.~* Enrollment in a conflicting and/or Investigational New Drug (IND) clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- Inhaled PGE1 (150 ng/kg/min) (Type: ACTIVE_COMPARATOR): 150 ng/kg/min Inhaled PGE1
- Aerosolized Normal Saline (Type: PLACEBO_COMPARATOR): Eligible infants will be randomly assigned to either IPGE1 \[150ng/kg/min\], IPGE1 \[300ng/kg/min\] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
- Inhaled PGE1 (300 ng/kg/min) (Type: ACTIVE_COMPARATOR): 300 ng/kg/min of Inhaled PGE1

Based on this trial design, predict the completion outcome and termination type (if applicable).